Compare Ishares Msci Spain ETF (EWP) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Spain ETF vs Novartis AG — how do they compare? Ishares Msci Spain ETF trades at $57.9 (market cap $2.30B), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 116.8× Ishares Msci Spain ETF's market cap, and Novartis AG pays a 3.31% dividend while Ishares Msci Spain ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Spain ETF for 41 Days and Novartis AG for 82 Days on average.
| EWP | NVS | |
|---|---|---|
Market Cap | $2.30B | $268.57B |
Volume | 845,747 | 1,532,573 |
Sector | Broad Market / Factor | Health |
52-Week High | $63.23 | $168.62 |
52-Week Low | $48.33 | $121.80 |
Typical Hold Time | 41 Days | 82 Days |
Enterprise Value | — | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWP, the iShares MSCI Spain ETF, trades at $57.90 with minimal daily movement (+0.14%). Technical indicators show a bearish trend with strong selling pressure across moving averages and oscillators. The ETF offers exposure to Spanish equities at a discounted valuation with a 2.7% yield, though concentrated in financials and utilities. Recent ECB rate hikes and energy price volatility create macroeconomic headwinds for European markets.
The outlook remains cautious given bearish technical signals and eurozone economic pressures. Attractive valuation and dividend yield provide support, but concentration risk and monetary policy tightening pose challenges. Further upside depends on Spanish economic resilience and stabilization of energy inflation.
NVS trades at $143.11, down 0.12% on the day, with a bearish technical signal and mixed earnings history including a recent Q1 2026 miss. The company maintains strong profitability with a 22.5% net income margin and 30.55% ROE, while recent news highlights a major $7.8B licensing deal with China's Abogen and ongoing investor scrutiny following clinical trial setbacks.
The outlook is cautious; analyst consensus is a Hold with a $146 price target, but risks include pipeline disappointments and M&A execution. Upside hinges on successful drug launches and deal integration, while downside stems from competitive pressures and regulatory challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Spain ETF
EWP is a country-specific ETF that tracks the performance of the Spanish equity market. It provides targeted access to large and mid-sized companies in Spain, with heavy weightings in financials and utilities like Banco Santander and Iberdrola.
Read more on EWP →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
